X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 65 filers reported holding X4 PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $428,000 | +54.0% | 250,144 | 0.0% | 0.26% | +60.7% |
| Q2 2022 | $278,000 | -36.5% | 250,144 | 0.0% | 0.16% | -19.3% |
| Q1 2022 | $438,000 | -43.8% | 250,144 | -26.5% | 0.20% | -47.7% |
| Q4 2021 | $780,000 | -61.8% | 340,495 | -11.9% | 0.39% | -58.0% |
| Q3 2021 | $2,044,000 | -6.0% | 386,475 | +15.5% | 0.92% | +13.6% |
| Q2 2021 | $2,175,000 | – | 334,684 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |